Showing studies matching your search1 results shown

Studies (1 shown)

NCT05856760PHASE2COMPLETED

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

Sponsor · Travere Therapeutics, Inc.Condition · Immunoglobulin A NephropathyIntervention · SparsentanUpdated Nov 2025
Showing top 1 results. See all 1 results on CT.gov →